View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 21, 2021updated 12 Jul 2022 11:19am

Fujifilm starts anti-influenza drug trial in Japan to treat Covid-19

Fujifilm Toyama Chemical has commenced a new Phase III clinical trial of its anti-influenza drug Avigan tablet (generic name: favipiravir) in Japan for treating Covid-19 patients. 

Fujifilm Toyama Chemical has commenced a new Phase III clinical trial of its anti-influenza drug Avigan tablet (generic name: favipiravir) in Japan for treating Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

In 2014, Avigan had received domestic manufacturing and marketing approval for treating new or re-emerging influenza viruses.

The drug works by selectively hindering RNA polymerase linked to influenza viral replication. The company expects that it could work against the novel coronavirus, which is also an RNA virus of the same kind as influenza viruses.

The double-blind, placebo-controlled clinical trial will analyse the efficacy and safety of the drug in patients with early-onset Covid-19 who are at the risk of progressing to severe symptoms.

It will enrol subjects aged 50 and above who are at risk of developing serious conditions, such as people with underlying diseases and obesity, within 72 hours of Covid-19 onset.

The ratio of patients who progress to severe disease in Avigan versus placebo groups will form the primary endpoint of the trial.

The design of the trial is based on the findings from a Phase III clinical study implemented last year, which showed that Avigan accelerated symptom improvement in early-onset Covid-19 patients.

In March last year, Fujifilm began a Phase III clinical trial of Avigan in Japan for treating Covid-19 patients with non-severe pneumonia.

The trial met the primary endpoint, with a statistically significant difference. The company filed an Application for Partial Changes for Avigan’s manufacturing and marketing approval.

Using 156 subjects as analysis targets, the median value of primary endpoints was 11.9 days for the Avigan group versus 14.7 days for the placebo group.

Fujifilm, in partnership with various strategic partners, is working on scaling up Avigan production for meeting the requests of the Japanese Government and other countries.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena